<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905056</url>
  </required_header>
  <id_info>
    <org_study_id>B2021-088R</org_study_id>
    <nct_id>NCT04905056</nct_id>
  </id_info>
  <brief_title>A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules</brief_title>
  <official_title>A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, two-center, single arm phase II clinical study to evaluate safety and&#xD;
      effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass&#xD;
      nodules&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 years</time_frame>
    <description>One year progression free survival after radiofrequency ablation of ground glass nodules</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 years, 3 years, 5years</time_frame>
    <description>overall survival after radiofrequency ablation of ground glass nodules</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Progression</condition>
  <arm_group>
    <arm_group_label>ablation therapy in the treatment of lung cancer presenting as ground-glass nodules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ablation therapy</intervention_name>
    <description>Ablation therapy in the treatment of lung cancer presenting as ground-glass nodules</description>
    <arm_group_label>ablation therapy in the treatment of lung cancer presenting as ground-glass nodules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 18 and 85 years;&#xD;
&#xD;
          2. GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having&#xD;
             been re-examined by thin-section CT);&#xD;
&#xD;
          3. The maximum diameter of the GGO is bigger than 8mm and smaller than 3cm;&#xD;
&#xD;
          4. For single GGO: obvious progress was observed in pure GGO or the solid component of&#xD;
             mixed ground glass nodules was more than or equal to 2 mm&#xD;
&#xD;
          5. The patients were unable to tolerate the operation for various reasons or multiple&#xD;
             grinding glass nodules, operation can not be completely removed; or patients had&#xD;
             received surgery in ipsilateral chest&#xD;
&#xD;
          6. The patient is able to understand and comply with the study and has provided written&#xD;
             informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who participated in any drug and / or medical device clinical trials within&#xD;
             one month before the trial&#xD;
&#xD;
          2. had severe disease conditions&#xD;
&#xD;
          3. allergy to narcotic drugs&#xD;
&#xD;
          4. had other autoimmune disease&#xD;
&#xD;
          5. dementia or cognitive impairment can't cooperate with researchers&#xD;
&#xD;
          6. any local treatment other than ablation was received within 4 weeks before the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qun Wang, Phd</last_name>
    <phone>86-21-64041990</phone>
    <email>13301050210@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Thoracic Surgery, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Wang, phd</last_name>
      <phone>86-21-64041990</phone>
      <email>13301050210@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 23, 2021</study_first_submitted>
  <study_first_submitted_qc>May 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 23, 2021</last_update_submitted>
  <last_update_submitted_qc>May 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Xi Junjie</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

